Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novavax In Vaccine Deal With Rovi

by Rick Mullin
July 13, 2009 | A version of this story appeared in Volume 87, Issue 28

Novavax is licensing its recombinant virus-like-particle (VLP) vaccine technology to Madrid-based Rovi Pharmaceuticals for the development of vaccines under an $83 million program sponsored by the Spanish Ministry of Health. Novavax, based in Rockville, Md., says it is also negotiating a broader licensing deal with Rovi under which the Spanish firm will receive exclusive licenses to Novavax' technology to commercialize flu vaccines in Spain and Portugal and nonexclusive licenses for Europe, Latin America, and Africa. According to Novavax, Rovi will make a $3 million equity investment in Novavax and has established a nonprofit foundation with a $35 million credit line from the Spanish government to commercialize VLP-based vaccines in the European Union starting in 2012.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.